Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neuroblastoma 9Sarcoma, Ewing 1Sarcoma 1Osteosarcoma 1

Interventions

Ifosfamide 15Methotrexate 12Doxorubicin 12Filgrastim 10Cisplatin 10Cyclophosphamide 9Etoposide 8Gemcitabine 7cabozantinib 6apatinib 6Magnetic Resonance Spectroscopy 6Leucovorin 6X-Rays 5Specimen Handling 5Sirolimus 5Phantoms, Imaging 5Nivolumab 5Neoadjuvant Therapy 5camrelizumab 4Vincristine 4Topotecan 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Drug Therapy 4Docetaxel 4Biopsy 4regorafenib 3palbociclib 3olaparib 3mifamurtide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Osteosarcoma × naxitamab × Clear all
NCT02502786 2025-10-07

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
46 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡